DOCSLIB.ORG

The Compelling Need for Game-Changing Influenza Vaccines

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Compelling Need for Game-Changing Influenza Vaccines THE COMPELLING NEED FOR GAME-CHANGING INFLUENZA VACCINES AN ANALYSIS OF THE INFLUENZA VACCINE ENTERPRISE AND RECOMMENDATIONS FOR THE FUTURE OCTOBER 2012 The Compelling Need for Game-Changing Influenza Vaccines An Analysis of the Influenza Vaccine Enterprise and Recommendations for the Future Michael T. Osterholm, PhD, MPH Nicholas S. Kelley, PhD Jill M. Manske, PhD, MPH Katie S. Ballering, PhD Tabitha R. Leighton, MPH Kristine A. Moore, MD, MPH The Center for Infectious Disease Research and Policy (CIDRAP), founded in 2001, is a global leader in addressing public health preparedness and emerging infectious disease response. Part of the Academic Health Center at the University of Minnesota, CIDRAP works to prevent illness and death from targeted infectious disease threats through research and the translation of scientific information into real-world, practical applications, policies, and solutions. For more information, visit: www.cidrap.umn.edu. This report was made possible in part by a grant from the Alfred P. Sloan Foundation. This report is available at: www.cidrap.umn.edu This report was produced and designed by Betsy Seeler Design. © 2012 Regents of the University of Minnesota. All rights reserved. Contents Preface...............................................................................................................................................................2 Executive Summary..........................................................................................................................................5 Chapter.1.. Understanding Influenza as a Vaccine-Preventable Disease.................................................10 Chapter.2... Currently Licensed Influenza Vaccines: Historical Perspective...............................................16 Chapter.3. Efficacy, Effectiveness, and Cost-Effectiveness of the Currently Licensed Influenza Vaccines.....................................................................................................................20 Chapter.4... How Safe Are Current Influenza Vaccines?.............................................................................35 Chapter.5... Public Acceptance of Influenza Vaccines.................................................................................40 Chapter.6... Seasonal and Pandemic Influenza Vaccine Availability .........................................................44 Chapter.7... Recommendations for Influenza Vaccine Use and Public Health Promotion .......................51 Chapter.8... Influenza Immunology: Infection, Current Vaccines, and New Developments....................65 Chapter.9... Potential Game-Changing Influenza Vaccines in the Research Pipeline: Framing the Discussion ............................................................................................................76 Chapter.10... Regulation of the Influenza Vaccine Enterprise.....................................................................84 Chapter.11.. Market Considerations, Challenges, and Barriers to Achieving Game-Changing Influenza Vaccines.....................................................................................................................92 Chapter.12... Public Health Policy Barriers to Achieving Game-Changing Influenza Vaccines ...............102 Chapter.13... Organization and Leadership Barriers to Achieving Novel-Antigen, Game-Changing Vaccines ......................................................................................................115 Chapter.14... Conclusions and Recommendations......................................................................................120 Appendix.A... List of Abbreviations..............................................................................................................124 Appendix.B....Reprint of Osterholm et al 2012 Lancet Infectious Diseases paper and Web appendix ...126 Preface ating back to Hippocrates, influenza has been many questions about the adequacy of our influenza and continues to be one of the “lion kings” of vaccine response. Dinfectious diseases. It occurs in two different patterns: (1) annual seasonal epidemics during winter In December 2009 the Alfred P. Sloan Foundation months in the temperate countries and year-round provided a grant to the Center for Infectious Disease in the tropics, and (2) global pandemics, which can Research and Policy (CIDRAP) at the University of occur during any season and last more than a year. An Minnesota to support the CIDRAP Comprehensive estimated 3,000 to 49,000 individuals in the United Influenza Vaccine Initiative (CCIVI). The primary States die every year from seasonal influenza. objectives of CCIVI were to provide a comprehensive review of all aspects of 2009-2010 pandemic Influenza pandemics occur when novel influenza A(H1N1)pdm09 influenza vaccine preparedness and viruses in animals undergo genetic changes that allow response based on the events of the pandemic vaccine the viruses to infect humans, who in turn transmit the effort and to review the scientific and programmatic new human-adapted virus to others. Four pandemics basis for the current seasonal influenza vaccine efforts. have occurred in the last 100 years: 1918, 1957, 1968, This review included all aspects of influenza vaccine and 2009. Influenza pandemics can vary in severity; research and development, financing, manufacturing, in 1918 an estimated 50 million to 100 million people efficacy, safety, regulatory issues, procurement, died worldwide. In the 1957 and 1968 pandemics, distribution, vaccine usage, public education, consumer an estimated 1.5 million and 750,000 people died, acceptance, and public policy. respectively. An official estimate of worldwide deaths from the 2009 pandemic is not expected until late 2012. And now, almost 3 years later, we share with you the completed CCIVI report; it represents one of the most Today more than 500 infectious diseases are known exhaustive reviews of any vaccine ever undertaken. When to occur in humans, yet in the United States, public we started, we had no idea where this initiative would health officials recommend routine childhood or adult take us. It was like peeling back the proverbial onion; vaccinations for only 17 of these diseases. And, for the more extensively we examined the “cradle to grave” only one of these diseases is there a recommendation aspects of our current seasonal and pandemic influenza for universal annual vaccination: namely, influenza. vaccines, the more questions—and lack of answers— In 2010 the Advisory Committee on Immunization we identified. In short, we found that current influenza Practices (ACIP) established the first national universal vaccine protection is substantially lower than for most seasonal influenza vaccination recommendation. routinely recommended vaccines and is suboptimal. It Annual vaccination is currently recommended with is clear, however, that during some influenza seasons trivalent inactivated influenza vaccine for all persons vaccination offers substantially more protection for most 6 months of age and older or with live-attenuated of the population than being unvaccinated. For this influenza vaccine for healthy nonpregnant persons reason, we believe current influenza vaccines will continue aged 2 to 49 years. Influenza vaccine availability also is to have a role in reducing influenza morbidity until more the cornerstone of influenza pandemic preparedness. effective interventions are available. But we can no longer accept the status quo regarding vaccine research and The Initiative development. In 2009, the world experienced its first influenza pandemic of the 21st century; it occurred 41 years This final CCIVI report includes 14 chapters and an after the previous one. Since the re-emergence of executive summary; it has 505 unique references. But H5N1 influenza in birds and humans in 2003 in to target the actions that we believe are necessary to Asia, the international public health community and move the international influenza vaccine enterprise influenza vaccine manufacturers have worked to toward critically needed novel-antigen, game-changing expand the global influenza vaccine manufacturing vaccines, we have identified just 10 key findings and capacity to respond to an emerging pandemic. six “high-level” recommendations. While our review However, early on in the 2009 pandemic there were and analysis effort was exhaustive, we have made every 2 effort to produce a report that allows the reader to The CCIVI Expert Advisory Group distinguish the forest from the trees! • Alfred Sommer, MD, MHS (Chair) Professor and Dean Emeritus, Johns Hopkins The Alfred P. Sloan Foundation generously provided Bloomberg School of Public Health unrestricted funding for the first year of the study • Ruth Berkelman, MD and allowed us to complete the final report when Director, Center for Public Health we finished our “onion peeling.” The remainder of Preparedness and Research, Emory University the support for this effort came from the general • Gail Cassell, PhD budget of CIDRAP and the ongoing efforts of a very Visiting Professor, Harvard Medical School dedicated CIDRAP team. We have no potential conflicts Ret. VP, Scientific Affairs and Distinguished of interest to report. In total, 13 CIDRAP staff and 2 Research Scholar, Eli Lilly and Company affiliated researchers provided thousands of hours of • Walt Dowdle, PhD painstaking “document detective work,” literature Consulting Director, the Task Force for Global review, and subject matter interviews. Health
Load more

Recommended publications
  • Influenza Virus Infections in Humans October 2018
    Influenza virus infections in humans October 2018 This note is provided in order to clarify the differences among seasonal influenza, pandemic influenza, and zoonotic or variant influenza. Seasonal influenza Seasonal influenza viruses circulate and cause disease in humans every year. In temperate climates, disease tends to occur seasonally in the winter months, spreading from person-to- person through sneezing, coughing, or touching contaminated surfaces. Seasonal influenza viruses can cause mild to severe illness and even death, particularly in some high-risk individuals. Persons at increased risk for severe disease include pregnant women, the very young and very old, immune-compromised people, and people with chronic underlying medical conditions. Seasonal influenza viruses evolve continuously, which means that people can get infected multiple times throughout their lives. Therefore the components of seasonal influenza vaccines are reviewed frequently (currently biannually) and updated periodically to ensure continued effectiveness of the vaccines. There are three large groupings or types of seasonal influenza viruses, labeled A, B, and C. Type A influenza viruses are further divided into subtypes according to the specific variety and combinations of two proteins that occur on the surface of the virus, the hemagglutinin or “H” protein and the neuraminidase or “N” protein. Currently, influenza A(H1N1) and A(H3N2) are the circulating seasonal influenza A virus subtypes. This seasonal A(H1N1) virus is the same virus that caused the 2009 influenza pandemic, as it is now circulating seasonally. In addition, there are two type B viruses that are also circulating as seasonal influenza viruses, which are named after the areas where they were first identified, Victoria lineage and Yamagata lineage.
    [Show full text]
  • (ACIP) General Best Guidance for Immunization
    8. Altered Immunocompetence Updates This section incorporates general content from the Infectious Diseases Society of America policy statement, 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host (1), to which CDC provided input in November 2011. The evidence supporting this guidance is based on expert opinion and arrived at by consensus. General Principles Altered immunocompetence, a term often used synonymously with immunosuppression, immunodeficiency, and immunocompromise, can be classified as primary or secondary. Primary immunodeficiencies generally are inherited and include conditions defined by an inherent absence or quantitative deficiency of cellular, humoral, or both components that provide immunity. Examples include congenital immunodeficiency diseases such as X- linked agammaglobulinemia, SCID, and chronic granulomatous disease. Secondary immunodeficiency is acquired and is defined by loss or qualitative deficiency in cellular or humoral immune components that occurs as a result of a disease process or its therapy. Examples of secondary immunodeficiency include HIV infection, hematopoietic malignancies, treatment with radiation, and treatment with immunosuppressive drugs. The degree to which immunosuppressive drugs cause clinically significant immunodeficiency generally is dose related and varies by drug. Primary and secondary immunodeficiencies might include a combination of deficits in both cellular and humoral immunity. Certain conditions like asplenia and chronic renal disease also can cause altered immunocompetence. Determination of altered immunocompetence is important to the vaccine provider because incidence or severity of some vaccine-preventable diseases is higher in persons with altered immunocompetence; therefore, certain vaccines (e.g., inactivated influenza vaccine, pneumococcal vaccines) are recommended specifically for persons with these diseases (2,3). Administration of live vaccines might need to be deferred until immune function has improved.
    [Show full text]
  • Financial Statements of Intercell AG As of December 31, 2010 According to UGB (Austrian GAAP)
    Financial Statements of Intercell AG as of December 31, 2010 according to UGB (Austrian GAAP) Intercell . STATUTORY FINANCIAL STATEMENTS . MMX Intercell . STATUTORY FINANCIAL STATEMENTS . MMX 01 // *. // Table of Contents I Balance Sheet 2 II Income Statement 4 III Notes 5 1. General principles 5 2. Summary of accounting and valuation method principles 5 3. Details of the balance sheet and income statement 6 4. Other information 11 Movement in fixed assets 16 IV Management Report 18 1. Report on the operation activities 18 2. Financial Review 24 3. Risks 25 4. Reporting on the internal control and risk management system regarding financial reporting 27 5. Disclosure according to Section 243a of the Austrian Commercial Code 28 6. Operational and Strategic Outlook 29 7. Events after the Balance Sheet Date 30 V Auditor’s Report 31 VI Declaration by the Management Board 33 *. Imprint 34 Intercell . STATUTORY FINANCIAL STATEMENTS . MMX 02 // I. // Balance Sheet December 31, 2010 December 31, 2009 A s s e t s EUR TEUR A. Fixed assets I. Intangible assets 1. Concessions, industrial property and similar rights and assets, and licenses in such rights and assets 19.029.092,52 3.793 2. Book value added by a merger 12.364.220,08 12.364 3. Prepayments 8.400,69 76 31.401.713,29 16.233 II. Tangible assets 1. Leasehold improvements 94.365,64 0 2. Machinery and equipment 1.880.222,07 1.915 3. Other equipments, factory and office equipment 357.854,84 380 2.332.442,55 2.295 III. Financial assets Shares in affiliated companies 4.954.970,54 130.117 38.689.126,38 148.645 B.
    [Show full text]
  • Assessment of Antigenic Difference of Equine Influenza Virus Strains by Challenge Study in Horses
    Accepted: 18 July 2016 DOI: 10.1111/irv.12418 SHORT ARTICLE Assessment of antigenic difference of equine influenza virus strains by challenge study in horses Takashi Yamanakaa | Manabu Nemotoa,b | Hiroshi Bannaia | Koji Tsujimuraa | Takashi Kondoa | Tomio Matsumuraa | Sarah Gildeab | Ann Cullinaneb aEquine Research Institute, Japan Racing Association, Shimotsuke, Tochigi, Japan We previously reported that horse antiserum against the Japanese equine influenza bVirology Unit, Irish Equine Centre, vaccine virus, A/equine/La Plata/1993 (LP93) exhibited reduced cross- neutralization Johnstown, Naas, Co. Kildare, Ireland against some Florida sublineage Clade (Fc) 2 viruses, for example, A/equine/Car- low/2011 (CL11). As a result, Japanese vaccine manufacturers will replace LP93 with Correspondence Takashi Yamanaka, Equine Research A/equine/Yokohama/aq13/2010 (Y10, Fc2). To assess the benefit of updating the Institute, Japan Racing Association, vaccine, five horses vaccinated with inactivated Y10 vaccine and five vaccinated with Shimotsuke, Tochigi, Japan. Email: [email protected] inactivated LP93 were challenged by exposure to a nebulized aerosol of CL11. The durations of pyrexia (≥38.5°C) and other adverse clinical symptoms experienced by the Y10 group were significantly shorter than those of the LP93 group. KEYWORDS challenge study, equine influenza, H3N8, inactivated whole vaccine 1 | INTRODUCTION showed limited cross- neutralization against some Fc2 viruses, for example, A/equine/Carlow/2011 (CL11) carrying the substitution Equine influenza
    [Show full text]
  • Characterizing Immunogenetic Factors Associated with Influenza Cross- Reactive Responses and Disease Severity
    Characterizing immunogenetic factors associated with Influenza cross- reactive responses and disease severity By Dr. Yoav Keynan M.D A Thesis submitted to the Faculty of Graduate Studies of The University of Manitoba in partial fulfilment of the requirements of the degree of DOCTOR OF PHILOSOPHY Department of Medical Microbiology University of Manitoba Winnipeg Copyright © 2013 by Yoav Keynan Acknowledgements: To my committee members: Dr. Coombs, Dr. Aoki, Dr. Soussi-gounni for your patience and invaluable advice, with diverse backgrounds, your input has been instrumental to the completion of this project. To my mentor, Dr. Fowke- for making my decision to migrate to your lab the best career decision I have made; for guiding me in this research project and for being an advocate and supporter along the course of the years. The most important lessons I have learned from you are not limited to science or grant writing, but more importantly, the optimism and positive attitude (sometimes bordering with delusion) that instills belief and motivation. To Dr. Rubinstein- for your advice and mentoring during the combined infectious diseases and PhD training. For the open doors, listening and support along the frequently bifurcating paths. To the Fowke lab team past and present- that make this lab a second home. Special thanks to Steve for your assistance over the past 8 years. To Dr. Plummer, for giving me the initial opportunity to embark on a research career in Winnipeg. To Dr. Ball for your support and collaboration. To the Ball Lab members, for the numerous fruitful discussions. To Dr. Meyers for the numerous projects and continued collaboration.
    [Show full text]
  • Dissertation Epidemiology, Ecology, and Evolution Of
    DISSERTATION EPIDEMIOLOGY, ECOLOGY, AND EVOLUTION OF CANINE INFLUENZA VIRUS H3N8 IN UNITED STATES DOGS Submitted by Heidi Lee Pecoraro Department of Microbiology, Immunology, and Pathology In partial fulfillment of the requirements For the Degree of Doctor of Philosophy Colorado State University Fort Collins, Colorado Fall 2012 Doctoral Committee: Advisor: Gabriele Landolt Carol Blair Richard Bowen Kathryn Huyvaert Copyright by Heidi Lee Pecoraro 2012 All Rights Reserved ABSTRACT EPIDEMIOLOGY, ECOLOGY, AND EVOLUTION OF CANINE INFLUENZA VIRUS H3N8 IN UNITED STATES DOGS Canine influenza virus (CIV) first emerged in dogs at a Florida racing track in 2004, although serological evidence suggests the virus has been circulating in the Unites States since as early as 1999. Phylogenetic analysis shows that CIV isolates are related to equine influenza virus of the Florida Clade 1 sublineage. However, sustained transmission of CIV among dogs and further genetic evolution of the virus has established CIV as a canine-specific influenza A virus (IAV). During the early years after emergence, studies determining the impact of CIV on dog populations were scarce. The few published findings were also alarming, with case fatality rates as high as 36% and seropositivity as high as 97% in certain dog populations. Despite these reports, the prevalence of CIV infection in dogs, the transmission dynamics among dog populations, risk factors for CIV infection, and how the virus was evolving within the canine host had yet to be examined. The research described here
    [Show full text]
  • Asplenia Vaccination Guide
    Stanford Health Care Vaccination Subcommitee Revision date 11/308/2018 Functional or Anatomical Asplenia Vaccine Guide I. PURPOSE To outline appropriate vaccines targeting encapsulated bacteria for functionally or anatomically asplenic patients. Routine vaccines that may also be indicated but not addressed here include influenza, Tdap, herpes zoster, HPV, MMR, and varicella.1,2,3 II. Background Functionally or anatomically asplenic patients should be vaccinated to decrease the risk of sepsis due to organisms such as Streptococcus pneumoniae, Haemophilus influenzae type B, and Neisseria meningitidis. Guidelines are based on CDC recommendations. For additional information, see https://www.cdc.gov/vaccines/schedules/hcp/imz/adult-conditions.html. III. Procedures/Guidelines1,2,3,6,7,8 The regimen consists of 4 vaccines initially, followed by repeat doses as specified: 1. Haemophilus b conjugate (Hib) vaccine (ACTHIB®) IM once if they have not previously received Hib vaccine 2. Pneumococcal conjugate 13-valent (PCV13) vaccine (PREVNAR 13®) IM once • 2nd dose: Pneumococcal polysaccharide 23-valent (PPSV23) vaccine (PNEUMOVAX 23®) SQ/IM once given ≥ 8 weeks later, then 3rd dose as PPSV23 > 5 years later.4 Note: The above is valid for those who have not received any pneumococcal vaccines previously, or those with unknown vaccination history. If already received prior doses of PPSV23: give PCV13 at least 1 year after last PPSV23 dose. 3. Meningococcal conjugate vaccine (MenACWY-CRM, MENVEO®) IM (repeat in ≥ 8 weeks, then every 5 years thereafter) 4. Meningococcal serogroup B vaccine (MenB, BEXSERO®) IM (repeat in ≥ 4 weeks) Timing of vaccination relative to splenectomy: 1. Should be given at least 14 days before splenectomy, if possible.
    [Show full text]
  • Menhibrix® Meningococcal Groups C and Y and Haemophilus B Tetanus Toxoid Conjugate Vaccine
    MenHibrix® Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine Age Indications for Menhibrix ® Vaccine Vaccine Administration Menhibrix® (GSK): for aged 6 weeks through 18 months at increased - Intramuscular (IM) injection in the anterolateral aspect of risk for meningococcal disease (see below) the thigh for most infants younger than 1 year of age In older children, in the deltoid muscle of the arm Indications for Use and Schedule - Indicated for active immunization to prevent invasive disease - 1-1.5 inch, 22-25 gauge needle - Use professional judgment in selecting caused by Neisseria meningitidis serogroups C and Y and needle length Haemophilus influenzae type b. Storage and Handling - Four doses (0.5 mL each) by intramuscular injection at 2, 4, 6, and 12 through 15 months of age. The first dose may be - Store in the refrigerator between given as early as 6 weeks of age. The fourth dose may be 35º-46º F (2º-8º C); Do NOT freeze Hib-MenCY-TT given as late as 18 months of age. - Protect vials from light. - Keep in the original box · Minimum interval - 8 weeks between doses - Administer vaccine immediately after drawn up in syringe MenHibrix will be supplied to select providers designated by the Georgia Immunization Office. HIGH- RISK INFANTS 6 WEEKS THROUGH 18 MONTHS OF AGE: Persons with persistent complement component pathway deficiencies Persons with anatomic or functional asplenia Complex congenital heart disease with asplenia Sickle cell disease Persons living in or traveling to countries in which N. meningitidis is hyper-endemic or epidemic. CONTRAINDICATIONS • An anaphylactic (severe allergic) reaction to a prior dose or a component of any meningococcal-, H.
    [Show full text]
  • CDPH Letterhead
    State of California—Health and Human Services Agency California Department of Public Health KAREN L. SMITH, MD, MPH EDMUND G. BROWN JR. Director and State Health Officer Governor January 25, 2017 IZB-FY-16-17-07 TO: California Vaccines for Children (VFC) Program Providers FROM: Sarah Royce, M.D., M.P.H, Chief Immunization Branch SUBJECT: HIBERIX™ (HAEMOPHILUS INFLUENZAE TYPE B (HIB) CONJUGATE VACCINE) AVAILABLE FOR BOTH PRIMARY SERIES AND BOOSTER DOSE This memo is divided into sections to enable you to quickly access the information you need: Section Page(s) Summary 1 Background and Composition 2 Recommendations for Vaccine Use 2 Eligible Groups 2 Licensed Dosing Schedule 2 Current ACIP Recommendations 3 Minimum Ages and Intervals 3 Contraindications 3 Precautions 3 Vaccine Information Statement 3 Administration 3 Storage and Handling 4 Administration with Other Vaccines 4 Potential Vaccine Adverse Events 4 Reporting of Adverse Events and Errors 4 How Supplied 4 Ordering and Billing 5 Documentation 6 California Vaccines for Children Program 850 Marina Bay Parkway, Building P, 2nd Floor, Richmond, CA 94804 Toll free (877) 243-8832 ● FAX (877) 329-9832 ● Internet Address: www.eziz.org Hiberix Page 2 of 6 January 25, 2017 SUMMARY On January 14, 2016, the United States Food and Drug Administration (FDA) expanded the licensure of Hiberix™ (GlaxoSmithKline Biologicals [GSK]). It is now licensed for the primary Hib vaccination series at 2, 4, and 6 months of age, in addition to the previous indication for the booster dose. Hiberix™ is a Haemophilus influenzae type b conjugate (tetanus toxoid conjugate) vaccine indicated for active immunization for the prevention of invasive disease caused by Haemophilus influenzae type b for children 6 weeks through 4 years of age.
    [Show full text]
  • ESCMID Online Lecture Library © by Author
    Albert Osterhaus Head Dept Virology Chairman ESWI CSO Viroclinics-Biosciences BV Library Pandemic flu and the anti-H1N1 vaccine: Lecture a retrospective view. author Onlineby © ESCMID ESCMID conference on the impact of vaccines on Public Health Prague, 2nd April 2011 Human influenza: three appearances Library Seasonal influenza (A: H3N2, H1N1; B) Lecture Avian influenza author (A: H7N7, H5N1…)Online by © PandemicESCMID influenza (A: H1N1, H2N2, H3N2, H1N1…?) INFLUENZA A VIRUS Recent zoonotic transmissions Library Subtype Country Year # Cases # Deaths H7N7 UK Lecture1996 1 0 H5N1 Hongkong 1997 18 6 H9N2 SE-Asia 1999author >2 0 H5N1 HongkongOnlineby 2003 2? 1 H7N7 Netherlands© 2003 89 1 H7N2 USA 2003 1 0 H7N3 Canada 2004 2 0 H5N1ESCMIDSE-Asia/M-East/ 2003-11 .>500 >300* Europe/W-Africa *CFR ~ 60% Library Lecture author Onlineby © ESCMID Confirmed H5N1 avian influenza virus endemic areas (poultry and wild birds) since 2003 Avian influenza A H5N1 virus - HA: Receptor specificity - Library Shinya et al., Nature 440, 2006 Lecture Van Riel et al., Science 2006 author Van Riel et al., Online Am J Pathol 2007 by Van Riel et al., © Am J Pathol 2009 Van Riel et al., ESCMID Am J Pathol 2010 Library Lecture author Onlineby © ESCMID Introduction - Attachment to the upper respiratory tract - Seasonal H3N2 Pandemic H1N1 HPAIV H5N1 Last four pandemics Library Lecture Credit: US National Museum of Health and Medicine author 1918 1957Online 1968 2009 “Spanish Flu” “Asian Flu” by “Hong Kong Flu” © ”Swine Flu” >40 million deaths 1-4 million deaths 1-4million deaths ??? A(H1N1)ESCMIDA(H2N2) A(H3N2) A(H1N1) Library Lecture author Onlineby © ESCMID Air traffic from Mexico ~ 1998 PB2,PA: Triple reassortant ~ 1968 ~ 1998 PB1: LibraryN-America ~ 1918 Classical swine HA, NP, NS: Lecture ~ 1979 NA, MA: authorEurasian swine Eurasia Onlineby A/California/4/2009 © PB2 PB1 The H1N1v flu virus PA Courtesy: Ron Fouchier HA NP ESCMID NA MA NS Library Lecture author Onlineby © ESCMID The Mexican flu virus..
    [Show full text]
  • Not for Distribution in Australia, Canada, Japan Or the United States
    Not for distribution in Australia, Canada, Japan or the United States Proposed Merger of Equals between Vivalis and Intercell Creation of a European Biotech Leader in Vaccines and Antibodies Vivalis (“Vivalis”) and Intercell AG (“Intercell”) to merge and form Valneva SE (“Valneva”), headquartered in Lyon (France) and listed on the regulated markets of NYSE Euronext in Paris and the Vienna Stock Exchange Intercell shareholders to receive 13 Vivalis new ordinary shares for 40 Intercell shares, implying a 31.7% premium for Intercell shareholders based on the average share prices over the last three months Additionally, Intercell shareholders to receive 13 new preferred shares for 40 Intercell shares. Each preferred share to be converted into 0.4810 new Valneva ordinary shares in the event of successful approval of Intercell’s Pseudomonas vaccine Implied ownership of Valneva immediately post-merger completion: 55% former Vivalis shareholders / 45% former Intercell shareholders Merger unanimously approved by the Supervisory Boards of Vivalis and Intercell Irrevocable undertakings to vote in favor of the merger received from holders of 68.5% of the voting rights in Vivalis, including Groupe Grimaud Fully committed EUR 40 million rights issue to be launched shortly after merger completion, to further strengthen Valneva’s financial profile. The Fonds Stratégique d'Investissement (“FSI”) supports the merger and will participate in the rights issue Merger of Equals structure with each company contributing equally to Valneva’s Supervisory Board, and Valneva’s Management Board being comprised of two Vivalis and two Intercell Management Board members Not for distribution in Australia, Canada, Japan or the United States Nantes (France) and Vienna (Austria), Dec.
    [Show full text]
  • Evolution and Divergence of H3N8 Equine Influenza Viruses
    pathogens Article Evolution and Divergence of H3N8 Equine Influenza Viruses Circulating in the United Kingdom from 2013 to 2015 Adam Rash 1,*, Rachel Morton 1, Alana Woodward 1, Olivia Maes 1, John McCauley 2, Neil Bryant 1 and Debra Elton 1 1 Animal Health Trust, Lanwades Park, Kentford, Newmarket, CB8 7UU, UK; [email protected] (R.M.); [email protected] (A.W.); [email protected] (O.M.); [email protected] (N.B.); [email protected] (D.E.) 2 Crick Worldwide Influenza Centre, The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK; [email protected] * Correspondence: [email protected]; Tel.: +44-01638-751000 (ext. 1228) Academic Editor: Janet M. Daly Received: 22 December 2016; Accepted: 22 January 2017; Published: 8 February 2017 Abstract: Equine influenza viruses (EIV) are a major cause of acute respiratory disease in horses worldwide and occasionally also affect vaccinated animals. Like other influenza A viruses, they undergo antigenic drift, highlighting the importance of both surveillance and virus characterisation in order for vaccine strains to be kept up to date. The aim of the work reported here was to monitor the genetic and antigenic changes occurring in EIV circulating in the UK from 2013 to 2015 and to identify any evidence of vaccine breakdown in the field. Virus isolation, reverse transcription polymerase chain reaction (RT-PCR) and sequencing were performed on EIV-positive nasopharyngeal swab samples submitted to the Diagnostic Laboratory Services at the Animal Health Trust (AHT). Phylogenetic analyses were completed for the haemagglutinin-1 (HA1) and neuraminidase (NA) genes using PhyML and amino acid sequences compared against the current World Organisation for Animal Health (OIE)-recommended Florida clade 2 vaccine strain.
    [Show full text]